A frank look at the cost structure of an IVF cycle and where it is reasonable — and where it is not — to optimise spend. The low-cost airline analogy: cheap tickets can fly you, but the trip changes. NHSU reimbursement reality, the value of cumulative live birth per cost, and the line between rational economy and over-optimisation.
Gonadotrophin spend is the single largest variable cost in a typical IVF cycle. Generic vs originator gonadotrophin choice matters — French registry data show originator FSH yields about 17% higher live birth than biosimilar in real-world use. Optimisation that lowers per-cycle cost can raise total cost per live birth when cumulative success drops. NHSU package mechanics determine where savings translate into clinic income and where they do not.
Calculate cost-per-live-birth, not cost-per-cycle, when comparing protocol options. Choose generic gonadotrophin where evidence supports equivalence; choose originator where it does not. Negotiate NHSU coverage and out-of-pocket boundaries explicitly with patients to avoid surprise costs mid-cycle.
Cost data are region-specific and date quickly; numbers in this lecture are 2026-Ukraine context. NHSU mechanisms change; rules valid at recording may shift. Pharmacoeconomic decisions should not erode informed consent or treatment access for the patient.
The analogy with low-cost airlines helps explain the logic: the basic service must be safe and standardized, while add-ons should be deliberate and justified. Cheaper does not mean worse if the quality of the key stage does not suffer; but economizing on a critical link is unacceptable.
The key metric is not the price of a single cycle but the cumulative probability of live birth per unit of cost, taking into account all transfers from one stimulation. A protocol that is more expensive per cycle but yields more embryos and transfers may prove more cost-effective when calculated per outcome.
Generics versus original gonadotropins are a subject of constant debate: given proven bioequivalence the price difference is justified, but quality control and comparability of results are required. The decision is made at the level of the clinic and the system, not by the price tag alone.
NHSU realities and public funding set the thresholds of optimization: a limited budget forces the search for protocols with the best outcome-to-cost ratio rather than the lowest price. The lecture concludes that a rational choice is built on cumulative effectiveness, safety and a transparent cost structure.
We can save money anywhere in an IVF cycle — the real question is what we pay for that. A frank look at the cost structure of stimulation, the low-cost-airline analogy, NHSU reimbursement realities and how to find a defensible balance between price and result without compromising live-birth rate.
Professor, MD, PhD, and Head of Sona Academy at Sona Group; an expert in reproductive medicine focusing on medical education and scientific strategy. He initiates and leads the group's educational and scientific programmes, including the Winter School of Reproductology and satellite scientific events.
Author of the lecture "Pharmacoeconomics of Ovulation Stimulation: Rational Choice in ART"
-1.png&w=3840&q=75)
